Header Logo

Connection

Fernando Martinez to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Fernando Martinez has written about Treatment Outcome.
Fernando Martinez
Connection Strength
3.102
Treatment Outcome
  1. Richeldi L, Schiffman C, Behr J, Inoue Y, Corte TJ, Cottin V, Jenkins RG, Nathan SD, Raghu G, Walsh SLF, Jayia PK, Kamath N, Martinez FJ. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial. Am J Respir Crit Care Med. 2024 05 01; 209(9):1132-1140.
    View in: PubMed
    Score: 0.107
  2. Martinez FJ, Criner GJ, Gessner C, Jandl M, Scherbovsky F, Shinkai M, Siler TM, Vogelmeier CF, Voves R, Wedzicha JA, Bartels C, Bottoli I, Byiers S, Cardenas P, Eckert JH, Gutzwiller FS, Knorr B, Kothari M, Parlikar R, Tanase AM, Franssen FME. Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial. Am J Respir Crit Care Med. 2023 08 15; 208(4):417-427.
    View in: PubMed
    Score: 0.102
  3. Martinez FJ, Wijsenbeek MS, Raghu G, Flaherty KR, Maher TM, Wuyts WA, Kreuter M, Kolb M, Chambers DC, Fogarty C, Mogulkoc N, Tutuncu AS, Richeldi L. Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). Am J Respir Crit Care Med. 2022 05 01; 205(9):1084-1092.
    View in: PubMed
    Score: 0.093
  4. Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Trivedi R, Jenkins M, Darken P, Aurivillius M, Dorinsky P. Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021 Aug-Sep; 185:106509.
    View in: PubMed
    Score: 0.088
  5. Singh D, Donohue JF, Boucot IH, Barnes NC, Compton C, Martinez FJ. Future concepts in bronchodilation for COPD: dual- versus monotherapy. Eur Respir Rev. 2021 Jun 30; 30(160).
    View in: PubMed
    Score: 0.087
  6. Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, Sciurba FC, Raghu G, Brooks MM, Kim DY, Dilling DF, Criner GJ, Kim H, Belloli EA, Nambiar AM, Scholand MB, Anstrom KJ, Noth I. Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. JAMA. 2021 05 11; 325(18):1841-1851.
    View in: PubMed
    Score: 0.087
  7. Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. Int J Chron Obstruct Pulmon Dis. 2020; 15:99-106.
    View in: PubMed
    Score: 0.079
  8. Behr J, Kolb M, Song JW, Luppi F, Schinzel B, Stowasser S, Quaresma M, Martinez FJ. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). Am J Respir Crit Care Med. 2019 12 15; 200(12):1505-1512.
    View in: PubMed
    Score: 0.079
  9. Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Gr?nke L, Vo? F, Singh D. Effects of baseline symptom burden on treatment response in COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:181-194.
    View in: PubMed
    Score: 0.074
  10. Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Rom?n J, Purkayastha D, Bagul N, Rennard SI. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. Am J Respir Crit Care Med. 2018 11 15; 198(10):1268-1278.
    View in: PubMed
    Score: 0.073
  11. Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev. 2018 Sep 30; 27(149).
    View in: PubMed
    Score: 0.072
  12. Martinez FJ, Fabbri LM, Ferguson GT, Orevillo C, Darken P, Martin UJ, Reisner C. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. Chest. 2017 12; 152(6):1169-1178.
    View in: PubMed
    Score: 0.067
  13. Martinez FJ, Vestbo J, Anderson JA, Brook RD, Celli BR, Cowans NJ, Crim C, Dransfield M, Kilbride S, Yates J, Newby DE, Niewoehner D, Calverley PM. Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. Am J Respir Crit Care Med. 2017 04 01; 195(7):881-888.
    View in: PubMed
    Score: 0.065
  14. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015 Mar 07; 385(9971):857-66.
    View in: PubMed
    Score: 0.056
  15. Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med. 2014 Aug; 108(8):1171-9.
    View in: PubMed
    Score: 0.054
  16. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC, Albert R, Woodruff P, Martinez FJ. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014 Jun 15; 189(12):1503-8.
    View in: PubMed
    Score: 0.054
  17. Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM. Fluticasone furoate/vilanterol (100/25; 200/25 ?g) improves lung function in COPD: a randomised trial. Respir Med. 2013 Apr; 107(4):550-9.
    View in: PubMed
    Score: 0.049
  18. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24; 366(21):1968-77.
    View in: PubMed
    Score: 0.047
  19. Dransfield MT, Cockcroft JR, Townsend RR, Coxson HO, Sharma SS, Rubin DB, Emmett AH, Cicale MJ, Crater GD, Martinez FJ. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med. 2011 Sep; 105(9):1322-30.
    View in: PubMed
    Score: 0.044
  20. Rennard SI, Calverley PM, Goehring UM, Bredenbr?ker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res. 2011 Jan 27; 12:18.
    View in: PubMed
    Score: 0.043
  21. Han MK, Swigris J, Liu L, Bartholmai B, Murray S, Giardino N, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Flaherty K, Martinez FJ. Gender influences Health-Related Quality of Life in IPF. Respir Med. 2010 May; 104(5):724-30.
    View in: PubMed
    Score: 0.040
  22. Clark NM, Dodge JA, Partridge MR, Martinez FJ. Focusing on outcomes: making the most of COPD interventions. Int J Chron Obstruct Pulmon Dis. 2009; 4:61-77.
    View in: PubMed
    Score: 0.038
  23. Chang AC, Chan KM, Martinez FJ. Lessons from the national emphysema treatment trial. Semin Thorac Cardiovasc Surg. 2007; 19(2):172-80.
    View in: PubMed
    Score: 0.032
  24. Martinez FJ. Acute exacerbation of chronic bronchitis: expanding short-course therapy. Int J Antimicrob Agents. 2005 Dec; 26 Suppl 3:S156-63.
    View in: PubMed
    Score: 0.030
  25. Martinez FJ, Grossman RF, Zadeikis N, Fisher AC, Walker K, Ambruzs ME, Tennenberg AM. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J. 2005 Jun; 25(6):1001-10.
    View in: PubMed
    Score: 0.029
  26. Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2203-2214.
    View in: PubMed
    Score: 0.029
  27. Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.
    View in: PubMed
    Score: 0.029
  28. Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, Bourbeau J, Korn S, Bafadhel M, Han MK, Kolterer S, Miller K, Mouneimne D, Fletcher J, Mayer B, Min J, Pavord ID. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med. 2025 May 01; 392(17):1710-1720.
    View in: PubMed
    Score: 0.029
  29. Martinez FJ, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2005 Apr; 26(2):167-91.
    View in: PubMed
    Score: 0.028
  30. Wade RC, Martinez FJ, Criner GJ, Tombs L, Lipson DA, Halpin DMG, Han MK, Singh D, Wise RA, Kalhan R, Dransfield MT. ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD. Eur Respir J. 2025 Feb; 65(2).
    View in: PubMed
    Score: 0.028
  31. Singh D, Martinez FJ, Hurst JR, Han MK, Gale CP, Fredriksson M, Kisielewicz D, Mushunje A, Movitz C, Ojili N, Parikh H, Arya N, Bowen K, Patel M. Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). Am J Respir Crit Care Med. 2025 Feb; 211(2):205-214.
    View in: PubMed
    Score: 0.028
  32. Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, Ogura T, Suda T, Wijsenbeek M, Berkowitz E, Elpers B, Kim S, Watanabe H, Fischer A, Maher TM. Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Am J Respir Crit Care Med. 2025 Feb; 211(2):230-238.
    View in: PubMed
    Score: 0.028
  33. Whalen W, Berger K, Kim JS, Simmons W, Ma SF, Kaner RJ, Martinez FJ, Anstrom KJ, Parfrey H, Maher TM, Hammond M, Clark AB, Thickett D, Jenkins RG, Wilson AM, Noth I. TOLLIP SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):508-511.
    View in: PubMed
    Score: 0.027
  34. Kim JS, Murray S, Yow E, Anstrom KJ, Kim HJ, Flaherty KR, Martinez FJ, Noth I. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study. Chest. 2024 May; 165(5):1163-1173.
    View in: PubMed
    Score: 0.026
  35. Maher TM, Stowasser S, Voss F, Bendstrup E, Kreuter M, Martinez FJ, Sime PJ, Stock C. Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis. Respirology. 2023 12; 28(12):1147-1153.
    View in: PubMed
    Score: 0.025
  36. Podolanczuk AJ, Kim JS, Cooper CB, Lasky JA, Murray S, Oldham JM, Raghu G, Flaherty KR, Spino C, Noth I, Martinez FJ. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. BMC Pulm Med. 2022 Dec 13; 22(1):475.
    View in: PubMed
    Score: 0.024
  37. Raghu G, Mouded M, Chambers DC, Martinez FJ, Richeldi L, Lancaster LH, Hamblin MJ, Gibson KF, Rosas IO, Prasse A, Zhao G, Serenko M, Novikov N, McCurley A, Bansal P, Stebbins C, Arefayene M, Ibebunjo S, Violette SM, Gallagher D, Behr J. A Phase IIb Randomized Clinical Study of an Anti-av?6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 11 01; 206(9):1128-1139.
    View in: PubMed
    Score: 0.024
  38. Han MK, Ye W, Wang D, White E, Arjomandi M, Barjaktarevic IZ, Brown SA, Buhr RG, Comellas AP, Cooper CB, Criner GJ, Dransfield MT, Drescher F, Folz RJ, Hansel NN, Kalhan R, Kaner RJ, Kanner RE, Krishnan JA, Lazarus SC, Maddipati V, Martinez FJ, Mathews A, Meldrum C, McEvoy C, Nyunoya T, Rogers L, Stringer WW, Wendt CH, Wise RA, Wisniewski SR, Sciurba FC, Woodruff PG. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. N Engl J Med. 2022 09 29; 387(13):1173-1184.
    View in: PubMed
    Score: 0.024
  39. Thompson PJ, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lipson DA, Maghzal GJ, Martinez FJ, Midwinter D, Singh D, Tombs L, Wise RA. Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial. Respirology. 2022 12; 27(12):1034-1044.
    View in: PubMed
    Score: 0.024
  40. Cottin V, Martinez FJ, Jenkins RG, Belperio JA, Kitamura H, Molina-Molina M, Tschoepe I, Coeck C, Lievens D, Costabel U. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respir Res. 2022 Apr 07; 23(1):85.
    View in: PubMed
    Score: 0.023
  41. Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 2022 03 15; 205(6):674-684.
    View in: PubMed
    Score: 0.023
  42. Flaherty KR, Kazerooni EA, Curtis JL, Iannettoni M, Lange L, Schork MA, Martinez FJ. Short-term and long-term outcomes after bilateral lung volume reduction surgery : prediction by quantitative CT. Chest. 2001 May; 119(5):1337-46.
    View in: PubMed
    Score: 0.022
  43. Dransfield MT, Crim C, Criner GJ, Day NC, Halpin DMG, Han MK, Jones CE, Kilbride S, LaFon D, Lipson DA, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Lange P. Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. Ann Am Thorac Soc. 2021 05; 18(5):788-798.
    View in: PubMed
    Score: 0.022
  44. Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Lettis S, Lipson DA, Mannino D, Martin N, Martinez FJ, Miller BE, Wise R, Zhu CQ, Lomas D. InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respir Res. 2021 Apr 28; 22(1):130.
    View in: PubMed
    Score: 0.022
  45. Flaherty KR, Toews GB, Lynch JP, Kazerooni EA, Gross BH, Strawderman RL, Hariharan K, Flint A, Martinez FJ. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med. 2001 Mar; 110(4):278-82.
    View in: PubMed
    Score: 0.021
  46. Rabe KF, Martinez FJ, Singh D, Trivedi R, Jenkins M, Darken P, Aurivillius M, Dorinsky P. Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. Ther Adv Respir Dis. 2021 Jan-Dec; 15:17534666211034329.
    View in: PubMed
    Score: 0.021
  47. Zisman DA, Lynch JP, Toews GB, Kazerooni EA, Flint A, Martinez FJ. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest. 2000 Jun; 117(6):1619-26.
    View in: PubMed
    Score: 0.020
  48. Halpin DMG, Dransfield MT, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, Pascoe S, Singh D, Wise R, Criner GJ. The effect of exacerbation history on outcomes in the IMPACT trial. Eur Respir J. 2020 05; 55(5).
    View in: PubMed
    Score: 0.020
  49. Crim C, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Brook RD. Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial. Am J Respir Crit Care Med. 2020 05 15; 201(10):1307-1310.
    View in: PubMed
    Score: 0.020
  50. Anstrom KJ, Noth I, Flaherty KR, Edwards RH, Albright J, Baucom A, Brooks M, Clark AB, Clausen ES, Durheim MT, Kim DY, Kirchner J, Oldham JM, Snyder LD, Wilson AM, Wisniewski SR, Yow E, Martinez FJ. Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. Respir Res. 2020 Mar 12; 21(1):68.
    View in: PubMed
    Score: 0.020
  51. Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Paine Iii R, Bhatt SP, Bhakta NR, Arjomandi M, Kaner RJ, Pirozzi CS, Curtis JL, O'Neal WK, Woodruff PG, Han MK, Martinez FJ, Hansel N, Wells JM, Ortega VE, Hoffman EA, Doerschuk CM, Kim V, Dransfield MT, Drummond MB, Bowler R, Criner G, Christenson SA, Ronish B, Peters SP, Krishnan JA, Tashkin DP, Cooper CB. Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis. Int J Chron Obstruct Pulmon Dis. 2019; 14:2927-2938.
    View in: PubMed
    Score: 0.020
  52. Christensen PJ, Paine R, Curtis JL, Kazerooni EA, Iannettoni MD, Martinez FJ. Weight gain after lung volume reduction surgery is not correlated with improvement in pulmonary mechanics. Chest. 1999 Dec; 116(6):1601-7.
    View in: PubMed
    Score: 0.020
  53. Casanova N, Zhou T, Gonzalez-Garay ML, Rosas IO, Goldberg HJ, Ryter SW, Collard HR, El-Chemaly S, Flaherty KR, Hunninghake GM, Lasky JA, Lederer DJ, Machado RF, Martinez FJ, Noth I, Raghu G, Choi AMK, Garcia JGN. Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. Sci Rep. 2019 10 15; 9(1):14802.
    View in: PubMed
    Score: 0.019
  54. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Reisner C, Dorinsky P. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6??g and 160/18/9.6??g using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respir Med. 2019 Oct - Nov; 158:59-66.
    View in: PubMed
    Score: 0.019
  55. Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med. 2019 09; 7(9):780-790.
    View in: PubMed
    Score: 0.019
  56. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019 09; 7(9):745-756.
    View in: PubMed
    Score: 0.019
  57. Celli BR, Anderson JA, Brook R, Calverley P, Cowans NJ, Crim C, Dixon I, Kim V, Martinez FJ, Morris A, Newby DE, Yates J, Vestbo J. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respir Res. 2019; 6(1):e000431.
    View in: PubMed
    Score: 0.019
  58. Krishnan JK, Voelker H, Connett JE, Niewoehner DE, Albert RK, Scanlon PD, Criner GJ, Dransfield MT, Han MK, Martinez FJ. Effect of daily azithromycin therapy and adherence on readmission risk in COPD. Eur Respir J. 2019 03; 53(3).
    View in: PubMed
    Score: 0.019
  59. Herrera C, Torres A, Garc?a-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Bone Marrow Transplant. 1999 Mar; 23(5):443-50.
    View in: PubMed
    Score: 0.019
  60. Laradi A, Mallet A, Beaufils H, Allouache M, Martinez F. HIV-associated nephropathy: outcome and prognosis factors. Groupe d' Etudes N?phrologiques d'Ile de France. J Am Soc Nephrol. 1998 Dec; 9(12):2327-35.
    View in: PubMed
    Score: 0.018
  61. Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018 10; 6(10):747-758.
    View in: PubMed
    Score: 0.018
  62. Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018 11 01; 379(18):1722-1731.
    View in: PubMed
    Score: 0.018
  63. Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I, Scholand MB, Cello J, Ho LA, Pipavath S, Lee JS, Lin J, Maloney J, Martinez FJ, Morrow E, Patti MG, Rogers S, Wolters PJ, Yates R, Anstrom KJ, Collard HR. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med. 2018 09; 6(9):707-714.
    View in: PubMed
    Score: 0.018
  64. Cazzola M, Calzetta L, Barnes PJ, Criner GJ, Martinez FJ, Papi A, Gabriella Matera M. Efficacy and safety profile of xanthines in COPD: a network meta-analysis. Eur Respir Rev. 2018 Jun 30; 27(148).
    View in: PubMed
    Score: 0.018
  65. Putcha N, Paul GG, Azar A, Wise RA, O'Neal WK, Dransfield MT, Woodruff PG, Curtis JL, Comellas AP, Drummond MB, Lambert AA, Paulin LM, Fawzy A, Kanner RE, Paine R, Han MK, Martinez FJ, Bowler RP, Barr RG, Hansel NN. Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. PLoS One. 2018; 13(4):e0194924.
    View in: PubMed
    Score: 0.018
  66. Gay SE, Kazerooni EA, Toews GB, Lynch JP, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, Popovich J, Hyzy R, Martinez FJ. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med. 1998 Apr; 157(4 Pt 1):1063-72.
    View in: PubMed
    Score: 0.018
  67. Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, Martinez FJ, Yates J, Newby DE, Vestbo J, Wise R, Celli BR. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. Am J Respir Crit Care Med. 2018 01 01; 197(1):47-55.
    View in: PubMed
    Score: 0.017
  68. Rosas IO, Goldberg HJ, Collard HR, El-Chemaly S, Flaherty K, Hunninghake GM, Lasky JA, Lederer DJ, Machado R, Martinez FJ, Maurer R, Teller D, Noth I, Peters E, Raghu G, Garcia JGN, Choi AMK. A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest. 2018 01; 153(1):94-104.
    View in: PubMed
    Score: 0.017
  69. Rabe KF, Calverley PMA, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J. 2017 07; 50(1).
    View in: PubMed
    Score: 0.017
  70. Duffy S, Marron R, Voelker H, Albert R, Connett J, Bailey W, Casaburi R, Cooper JA, Curtis JL, Dransfield M, Han MK, Make B, Marchetti N, Martinez F, Lazarus S, Niewoehner D, Scanlon PD, Sciurba F, Scharf S, Reed RM, Washko G, Woodruff P, McEvoy C, Aaron S, Sin D, Criner GJ. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respir Res. 2017 06 19; 18(1):124.
    View in: PubMed
    Score: 0.017
  71. Ra SW, Sze MA, Lee EC, Tam S, Oh Y, Fishbane N, Criner GJ, Woodruff PG, Lazarus SC, Albert R, Connett JE, Han MK, Martinez FJ, Aaron SD, Reed RM, Man SFP, Sin DD. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Respir Res. 2017 05 30; 18(1):109.
    View in: PubMed
    Score: 0.017
  72. Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, Magder S, Martinez FJ, Rajagopalan S, Vestbo J, Yates J, Newby DE. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017 10; 103(19):1536-1542.
    View in: PubMed
    Score: 0.016
  73. Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respir Res. 2017 01 06; 18(1):8.
    View in: PubMed
    Score: 0.016
  74. Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, Wells AU, Whelan TP, Wuyts W, Moreau E, Patterson SD, Smith V, Bayly S, Chien JW, Gong Q, Zhang JJ, O'Riordan TG. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med. 2017 01; 5(1):22-32.
    View in: PubMed
    Score: 0.016
  75. Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respir Med. 2016 11; 120:16-24.
    View in: PubMed
    Score: 0.016
  76. Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting ?2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Int J Chron Obstruct Pulmon Dis. 2016; 11:1921-8.
    View in: PubMed
    Score: 0.016
  77. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
    View in: PubMed
    Score: 0.016
  78. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016 Apr 30; 387(10030):1817-26.
    View in: PubMed
    Score: 0.015
  79. Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, Lancaster L, Gibson KF, Haddad T, Agarwal P, Mack M, Dasgupta B, Nnane IP, Flavin SK, Barnathan ES. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015 Dec; 46(6):1740-50.
    View in: PubMed
    Score: 0.015
  80. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agust? AA, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir Rev. 2015 Jun; 24(136):159-72.
    View in: PubMed
    Score: 0.014
  81. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J. 2015 Jul; 46(1):243-9.
    View in: PubMed
    Score: 0.014
  82. Scemla A, Gerber S, Duquesne A, Parize P, Martinez F, Anglicheau D, Snanoudj R, Zuber M, Bougnoux ME, Legendre C, Lortholary O. Dramatic improvement of severe cryptococcosis-induced immune reconstitution syndrome with adalimumab in a renal transplant recipient. Am J Transplant. 2015 Feb; 15(2):560-4.
    View in: PubMed
    Score: 0.014
  83. Aubert O, Bories MC, Suberbielle C, Snanoudj R, Anglicheau D, Rabant M, Martinez F, Scemla A, Legendre C, Sberro-Soussan R. Risk of antibody-mediated rejection in kidney transplant recipients with anti-HLA-C donor-specific antibodies. Am J Transplant. 2014 Jun; 14(6):1439-45.
    View in: PubMed
    Score: 0.013
  84. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013 Jul; 1(5):369-76.
    View in: PubMed
    Score: 0.013
  85. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 07; 158(9):641-9.
    View in: PubMed
    Score: 0.012
  86. Agusti A, Hurd S, Jones P, Fabbri LM, Martinez F, Vogelmeier C, Vestbo J, Rodriguez-Roisin R. FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J. 2013 Nov; 42(5):1391-401.
    View in: PubMed
    Score: 0.012
  87. Wedzicha JA, Rabe KF, Martinez FJ, Bredenbr?ker D, Brose M, Goehring UM, Calverley PMA. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013 May; 143(5):1302-1311.
    View in: PubMed
    Score: 0.012
  88. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
    View in: PubMed
    Score: 0.012
  89. Albert RK, Connett J, Curtis JL, Martinez FJ, Han MK, Lazarus SC, Woodruff PG. Mannose-binding lectin deficiency and acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2012; 7:767-77.
    View in: PubMed
    Score: 0.012
  90. Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, Haumann B, Martinez FJ, Yates J, Newby DE. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013 May; 41(5):1017-22.
    View in: PubMed
    Score: 0.012
  91. Sanchez-Garcia J, Serrano J, Serrano-Lopez J, Gomez-Garcia P, Martinez F, Garcia-Castellano JM, Rojas R, Martin C, Rodriguez-Villa A, Molina-Hurtado JR, Alvarez MA, Casa?o J, Torres-Gomez A. Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL. Bone Marrow Transplant. 2013 Mar; 48(3):396-402.
    View in: PubMed
    Score: 0.012
  92. Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis. 2012; 7:375-82.
    View in: PubMed
    Score: 0.012
  93. Tantisira KG, Damask A, Szefler SJ, Schuemann B, Markezich A, Su J, Klanderman B, Sylvia J, Wu R, Martinez F, Boushey HA, Chinchilli VM, Mauger D, Weiss ST, Israel E. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med. 2012 Jun 15; 185(12):1286-91.
    View in: PubMed
    Score: 0.012
  94. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012 May 15; 185(10):1044-8.
    View in: PubMed
    Score: 0.012
  95. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011 Aug 25; 365(8):689-98.
    View in: PubMed
    Score: 0.011
  96. Servais A, Meas-Yedid V, No?l LH, Martinez F, Panterne C, Kreis H, Zuber J, Timsit MO, Legendre Ch, Olivo-Marin JC, Thervet E. Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. Am J Transplant. 2011 Jul; 11(7):1456-63.
    View in: PubMed
    Score: 0.011
  97. Woodruff PG, Albert RK, Bailey WC, Casaburi R, Connett JE, Cooper JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Harnden SM, Kim V, Marchetti N, Martinez FJ, McEvoy CE, Niewoehner DE, Reilly JJ, Rice K, Scanlon PD, Scharf SM, Sciurba FC, Washko GR, Lazarus SC. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD. 2011 Feb; 8(1):21-9.
    View in: PubMed
    Score: 0.011
  98. Canaud G, Bienaim? F, No?l LH, Royal V, Alyanakian MA, Dautzenberg MD, Rabant M, Posson J, Thervet E, Anglicheau D, Kreis H, Martinez F, Legendre C, Zuber J. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant. 2010 Sep; 10(9):2051-60.
    View in: PubMed
    Score: 0.010
  99. Benzo RP, Chang CC, Farrell MH, Kaplan R, Ries A, Martinez FJ, Wise R, Make B, Sciurba F. Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease. Respiration. 2010; 80(1):10-8.
    View in: PubMed
    Score: 0.010
  100. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Candon S, Martinez F, Snanoudj R, Rabant M, Pallet N, Nochy D, Anglicheau D, Leruez M, Loupy A, Thervet E, Hermine O, Legendre C. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant. 2010 Mar; 10(3):681-6.
    View in: PubMed
    Score: 0.010
  101. Legendre Ch, Kreis H, Martinez F, Snanoudj R, Mamzer MF, Sberro R, Bererhi L, Anglicheau D, Zuber J, Loupy A, Thervet E, Pallet N, Sartorius A, Bertrand D, Canaud G, No?l LH, Rabant M, Timsit MO, M?jean A. Kidney transplantation at Necker Hospital: the most recent 5-year period (2004-2009). Clin Transpl. 2010; 127-32.
    View in: PubMed
    Score: 0.010
  102. Washko GR, Martinez FJ, Hoffman EA, Loring SH, Est?par RS, Diaz AA, Sciurba FC, Silverman EK, Han MK, Decamp M, Reilly JJ. Physiological and computed tomographic predictors of outcome from lung volume reduction surgery. Am J Respir Crit Care Med. 2010 Mar 01; 181(5):494-500.
    View in: PubMed
    Score: 0.010
  103. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009 Aug 29; 374(9691):685-94.
    View in: PubMed
    Score: 0.010
  104. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009 Aug 29; 374(9691):695-703.
    View in: PubMed
    Score: 0.010
  105. Benzo R, Farrell MH, Chang CC, Martinez FJ, Kaplan R, Reilly J, Criner G, Wise R, Make B, Luketich J, Fishman AP, Sciurba FC. Integrating health status and survival data: the palliative effect of lung volume reduction surgery. Am J Respir Crit Care Med. 2009 Aug 01; 180(3):239-46.
    View in: PubMed
    Score: 0.009
  106. Anglicheau D, Loupy A, Lefaucheur C, Pessione F, L?tourneau I, C?t? I, Gaha K, No?l LH, Patey N, Droz D, Martinez F, Zuber J, Glotz D, Thervet E, Legendre C. A simple clinico-histopathological composite scoring system is highly predictive of graft outcomes in marginal donors. Am J Transplant. 2008 Nov; 8(11):2325-34.
    View in: PubMed
    Score: 0.009
  107. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van M?lken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008 Feb; 31(2):416-69.
    View in: PubMed
    Score: 0.009
  108. Doherty DE, Chapman KR, Martinez FJ, Belfer MH. The value of early diagnosis for effective management of chronic obstructive pulmonary disease. J Fam Pract. 2007 Oct; 56(10 Suppl Value):S1-24.
    View in: PubMed
    Score: 0.008
  109. Anglicheau D, Loupy A, Suberbielle C, Zuber J, Patey N, No?l LH, Cavalcanti R, Le Quintrec M, Audat F, M?jean A, Martinez F, Mamzer-Bruneel MF, Thervet E, Legendre C. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study. Am J Transplant. 2007 May; 7(5):1185-92.
    View in: PubMed
    Score: 0.008
  110. Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents. 2007 Jan; 29(1):56-61.
    View in: PubMed
    Score: 0.008
  111. Chang AC, Chan KM, Lonigro RJ, Lau CL, Lama VN, Flaherty KR, Florn R, Pickens A, Murray S, Martinez FJ, Orringer MB. Surgical patient outcomes after the increased use of bilateral lung transplantation. J Thorac Cardiovasc Surg. 2007 Feb; 133(2):532-40.
    View in: PubMed
    Score: 0.008
  112. Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, Deschamps CC, Martinez FJ, Sciurba FC, Tonascia J, Fishman AP. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg. 2006 Aug; 82(2):431-43.
    View in: PubMed
    Score: 0.008
  113. Sciurba FC, Martinez FJ, Rogers RM, Make BJ, Criner GJ, Cherniack RM, Patel SA, Chu F, Coxson HO, Sharafkhaneh A, Elliot M, Luketich JD, Hogg JC. Relationship between pathologic characteristics of peripheral airways and outcome after lung volume reduction surgery in severe chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 Aug; 3(6):533-4.
    View in: PubMed
    Score: 0.008
  114. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003 May 22; 348(21):2059-73.
    View in: PubMed
    Score: 0.006
  115. Berenguer M, Prieto M, San Juan F, Ray?n JM, Martinez F, Carrasco D, Moya A, Orbis F, Mir J, Berenguer J. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 2002 Jul; 36(1):202-10.
    View in: PubMed
    Score: 0.006
  116. Fishman A, Fessler H, Martinez F, McKenna RJ, Naunheim K, Piantadosi S, Weinmann G, Wise R. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001 10 11; 345(15):1075-83.
    View in: PubMed
    Score: 0.006
  117. Quint LE, Bland PH, Walker JM, Kazerooni EA, Martinez FJ, Iannettoni MD, Bookstein FL. Diaphragmatic shape change after lung volume reduction surgery. J Thorac Imaging. 2001 Jul; 16(3):149-55.
    View in: PubMed
    Score: 0.005
  118. Jamadar DA, Kazerooni EA, Martinez FJ, Wahl RL. Semi-quantitative ventilation/perfusion scintigraphy and single-photon emission tomography for evaluation of lung volume reduction surgery candidates: description and prediction of clinical outcome. Eur J Nucl Med. 1999 Jul; 26(7):734-42.
    View in: PubMed
    Score: 0.005
  119. Whyte RI, Bria W, Martinez FJ, Lewis P, Bolling SF. Combined lung volume reduction and mitral valve reconstruction. Ann Thorac Surg. 1998 Oct; 66(4):1414-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.